Targeted biological treatment of solid tumours;Cílená biologická léčba solidních nádorů

Vnitrni Lekarstvi

Volumn 57, Issue 9, 2011, Pages 740-744

  Petruželka, Luboš ^a,b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Biomarkers; Individual treatment plan; Prediction; Targeted biological treatment; Treatment algorithm

Indexed keywords

BIOLOGICAL PRODUCT;

BREAST CANCER; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CANCER; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; METASTASIS; REVIEW; SOLID TUMOR;

HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 80053206209     PISSN: 0042773X     EISSN: 18017592     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Petruželka L. Pohled na vývoj onkologie ve 3. tisíciletí. Klin Onkol 2009; 22: 243-244.
2. Sawyers C. Targeted cancer therapy. Nature 2004; 432: 294-297. (Pubitemid 39551656)
3. Petruželka L, Novotný J, Závadová E. Principy molekulární bioregulační léčby. In: Cibula D, Petruželka L et al (eds). Onkogynekologie. Praha: Grada 2009.
4. Pink JJ, Jordan VC. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res 1996; 56: 2321-2330. (Pubitemid 26154081)
5. MacConaill LE, Garraway LA. Clinical Implications of the Cancer Genome. J Clin Oncol 2010; 28: 5219-5228.
6. Ramaswamy S, Perou CM. DNA microarrays in breast cancer: the promise of personalised medicine. Lancet 2003; 361: 1576-1577. (Pubitemid 36578989)
7. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002; 7 (Suppl 4): 2-8. (Pubitemid 34977157)
8. Stricker T, Catenacci DV, Seiwert TY. Molecular profilig of cancer - the future of personalized cancer medicine: a primer on cancer biology and tool necessary to bring molecular testing to the clinic. Semin Oncol 2011; 38: 173-185.
9. Petruželka L. Cílená molekulární biologická léčba karcinomu prsu. Referátový výběr z onkologie 2006; 23: 33-37.
10. Hanahan D, Weinberg RA. The Hallmarks of Cancer. Cell 2000; 100: 57-70. (Pubitemid 30046295)
11. Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell 2011; 144: 646-674.
12. Mountzios G, Soria JCH. Overview of Existing Therapies. In: Giaccone G, Soria JCH (eds). Targeted Therapies in Oncology. Informa healthcare 2007: 1-4.
13. Petruželka L, Petruželková L. Lapatinib. Farmakoterapie 2008; 4: 495-507.
14. Petruželka L. Cetuximab v první linii léčby kolorektálního karcinomu. Farmakoterapie 2008; 11: 320-321.
15. Gonzalez-Angulo AM, Hennessy BT, Mills GB. Future of Personalized Medicine in Oncology: A systems Biology Approach. J Clin Oncol 2010; 28: 2777-2783.
16. Schadt EE, Lamb J, Yang X et al. An integrative genomics approach to infer causal associations between gene expression and disease. Nat Genet 2005; 37: 710-717. (Pubitemid 41754887)
17. Tursz T, Fabrice AF, Lazar V et al. Implications of personalized medicine - perspective from a cancer center. Nat Rev Clin Oncol 2011; 8: 177-183.
18. Auffray C, Charron D, Hood L Predictive, preventive, personalized and participatory medicine: back to the future. Genome Med 2010; 2: 57-58.
19. Innocenti F, Cox NJ, Dolan ME. The use of genomic information to optimize cancer chemotherapy. Semin Oncol 2011; 38: 186-195.
20. Mendelsohn J, Tursz T, Schilsky RL et al. Focus on personalized medicine: WIN Consortium - challenges and advances. Nat Rev Clin Oncol 2011; 8: 133-134.
21. Petruželka L. Necílené podávání cílené biologické léčby aneb proč nemusí platit, kdo léčí více nemocných, léčí lépe. Edukační sborník XIV. dne profesora Staška 2009: Editorial.